High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

被引:379
|
作者
Lisio, Michael-Antony [1 ]
Fu, Lili [1 ]
Goyeneche, Alicia [1 ]
Gao, Zu-hua [1 ]
Telleria, Carlos [1 ]
机构
[1] McGill Univ, Dept Pathol, Expt Pathol Unit, Montreal, PQ H3A 2B4, Canada
关键词
high-grade serous ovarian cancer; cortical inclusion cysts; serous tubular intra-epithelial carcinoma; ovarian surface epithelium; homologous recombination; BRCA; mutant p53; genetically-engineered mouse models; debulking surgery; chemotherapy; TUBAL INTRAEPITHELIAL CARCINOMA; OLAPARIB MAINTENANCE THERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; GROSS RESIDUAL DISEASE; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; TP53; MUTATIONS; DOUBLE-BLIND;
D O I
10.3390/ijms20040952
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
引用
收藏
页数:33
相关论文
共 50 条
  • [31] Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
    Kieffer, Yann
    Bonneau, Claire
    Popova, Tatiana
    Rouzier, Roman
    Stern, Marc-Henri
    Mechta-Grigoriou, Fatima
    FRONTIERS IN GENETICS, 2020, 11
  • [32] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Ibrahim Yalcin
    Hanifi Sahin
    Mustafa Erkan Sari
    Asuman Nihan Haberal
    Eda Adeviye Sahin
    Husnu Celik
    Mehmet Mutlu Meydanli
    Ali Ayhan
    Indian Journal of Gynecologic Oncology, 2021, 19
  • [33] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Yalcin, Ibrahim
    Sahin, Hanifi
    Sari, Mustafa Erkan
    Haberal, Asuman Nihan
    Sahin, Eda Adeviye
    Celik, Husnu
    Meydanli, Mehmet Mutlu
    Ayhan, Ali
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [34] Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
    Wada, Miku
    Kukita, Asako
    Sone, Kenbun
    Hamamoto, Ryuji
    Kaneko, Syuzo
    Komatsu, Masaaki
    Takahashi, Yu
    Inoue, Futaba
    Kojima, Machiko
    Honjoh, Harunori
    Taguchi, Ayumi
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Tsuruga, Tetsushi
    Mori-Uchino, Mayuyo
    Wada-Hiraike, Osamu
    Osuga, Yutaka
    Fujii, Tomoyuki
    BIOMOLECULES, 2020, 10 (12) : 1 - 12
  • [35] mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
    Musa, Fernanda
    Alard, Amandine
    David-West, Gizelka
    Giuroiu, Iulia
    Blank, Stephanie
    Pothuri, Bhavana
    Curtin, John P.
    Schneider, Robert
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets
    Voutsadakis, Ioannis A.
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10423 - 10437
  • [37] Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients
    Feng, Zheng
    Wen, Hao
    Bi, Rui
    Duan, Yachen
    Yang, Wentao
    Wu, Xiaohua
    BMC CANCER, 2016, 16
  • [38] Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes
    Robertson, Sharon E.
    Yasukawa, Maya
    Marchion, Douglas C.
    Xiong, Yin
    Naqvi, Syeda Mahrukh Hussnain
    Gheit, Tarik
    Tommasino, Massimo
    Wenham, Robert M.
    Giuliano, Anna R.
    Lancaster, Johnathan M.
    Shahzad, Mian M. K.
    PLOS ONE, 2023, 18 (12):
  • [39] A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer
    Jin, Chengjuan
    Xue, Yingfeng
    Li, Yingwei
    Bu, Hualei
    Yu, Hongfeng
    Zhang, Tao
    Zhang, Zhiwei
    Yan, Shi
    Lu, Nan
    Kong, Beihua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 51 - 58
  • [40] Aberrant activation of the Hedgehog signalling pathway in high-grade serous ovarian cancer: a potential therapeutic target
    Pounds, R.
    Soo, J.
    Uddin, K.
    Dawson, C.
    Kehoe, S.
    Yap, J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 (08) : E37 - E37